Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Quidel and bioMerieux form global alliance to focus on rapid clinical diagnostics

BioMerieux : 15 January, 2008  (New Product)
Quidel and bioMerieux have formed a long-term global alliance to focus on rapid clinical diagnostics for the point-of-care.
bioMerieux will become Quidel’s primary distributor for its QuickVue rapid diagnostic tests outside the USA and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMerieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases.

bioMerieux will be the exclusive distributor of all of Quidel’s current QuickVue rapid diagnostic tests in all countries with the exception of the USA, Japan and Scandinavia, starting in May 2008. Branding for these products will reflect the strength and market power of both companies.

bioMerieux has over 1,900 sales, marketing and service representatives and a base of more than 45,000 instruments installed in over 150 countries worldwide. bioMerieux is a world leader in diagnostics for infectious diseases and has developed a very large library of biologics for its automated immunoassay systems, VIDAS and VIDIA.

“Quidel is pleased to be entering into a mutually beneficial alliance with a globally respected diagnostics leader that increases the reach of our products to markets around the world. Our intention is to create a partnership for co-development of a pipeline of new, high-value point-of-care tests intended to be sold in the USA by Quidel and in the rest of the world by bioMerieux exclusively,” said Caren Mason, president and CEO of Quidel.

“We are delighted with this very synergistic partnership with Quidel,” said Stephane Bancel, CEO of bioMerieux. “Quidel is recognised for the high quality of its products and its focus on providing accurate and cost-effective solutions to detect and minimize the spread of infectious diseases. Together, we will establish a global brand supporting clinicians’ decisions at their patients’ point-of-care.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo